Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics APLS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Apellis Pharmaceuticals Inc

APLS
Current price
17.69 USD -0.07 USD (-0.39%)
Last closed 17.76 USD
ISIN US03753U1060
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 232 112 384 USD
Yield for 12 month -53.96 %
1Y
3Y
5Y
10Y
15Y
APLS
21.11.2021 - 28.11.2021

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

35.35 USD

P/E ratio

Dividend Yield

Financials APLS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+781 367 000 USD

Last Year

+396 591 000 USD

Current Quarter

+166 797 000 USD

Last Quarter

+212 528 000 USD

Current Year

+663 644 000 USD

Last Year

+338 081 000 USD

Current Quarter

+132 437 000 USD

Last Quarter

+171 672 000 USD
EBITDA -184 418 000 USD
Operating Margin TTM -49.96 %
Price to Earnings
Return On Assets TTM -14.20 %
PEG Ratio
Return On Equity TTM -103.82 %
Wall Street Target Price 35.35 USD
Revenue TTM 775 838 976 USD
Book Value 1.31 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -3.20 %
Dividend Yield
Gross Profit TTM 314 676 000 USD
Earnings per share -1.80 USD
Diluted Eps TTM -1.80 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -28.83 %

Stock Valuation APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.02
Price Sales TTM 2.87
Enterprise Value EBITDA -12.12
Price Book MRQ 13.59

Technical indicators APLS

For 52 weeks

16.10 USD 42.47 USD
50 Day MA 18.33 USD
Shares Short Prior Month 27 245 432
200 Day MA 26.86 USD
Short Ratio 8.42
Shares Short 25 034 198
Short Percent 26.28 %